Guided Therapeutics and U.S. FDA Agree on Meeting Date to Plan Path Forward for LuViva Advanced Cervical Scan PMA

Guided Therapeutics and U.S. FDA Agree on Meeting Date to Plan Path Forward for LuViva® Advanced Cervical Scan Premarket Approval Application

November 6 Meeting to Review PMA Amendment; Meet New Reviewer

NORCROSS, Ga.--(BUSINESS WIRE)--

Guided Therapeutics, Inc. (GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today it will meet with the U.S. Food and Drug Administration (FDA) November 6, 2015, to review the company’s plan to submit an approvable application for the LuViva® Advanced Cervical Scan.

The LuViva is designed to detect cervical pre-cancer without taking a tissue sample and providing a result immediately, unlike any other women’s health cancer detection technology on the market. The LuViva is approved in Europe, Canada and Mexico, and is currently available to women in 20 countries.

The FDA, in a not approvable letter, recommended that the company include additional patient data as part of its next PMA amendment. A key objective of the scheduled meeting will be to determine the parameters of the additional patient data FDA is seeking.

The FDA also informed the company that it had appointed a new lead reviewer to head the Agency’s evaluation of LuViva. The lead reviewer coordinates FDA’s in-house team that assesses regulatory filings and also functions as the direct contact with Guided Therapeutics.

“We look forward to working with FDA and our new lead reviewer in order to achieve US approval for LuViva,” said Gene Cartwright, CEO of Guided Therapeutics. “Meanwhile, we are working with governments of several countries outside the U.S. to make the LuViva the standard of care for women’s health.”

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in our prior financings and our ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2014, and subsequent filings.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150915006052/en/

Contact:

IRTH Communications
Robert Haag, 866-976-4784
Managing Partner
gthp@irthcommunications.com

or

Guided Therapeutics, Inc.
Bill Wells, 770-242-8723

Help employers find you! Check out all the jobs and post your resume.

Back to news